Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
Minimal PT/aPTT effects by apixaban warrant caution in routine testing; leaves open need for standardized anti-Xa calibration across labs.
Article Effects of apixaban on prothrombin time, activated partial thromboplastin time and anti-Xa assays: a European survey was published on August 1, 2017 in the journal Clinical Chemistry and Laboratory Medicine (CCLM) (volume 55, issue 8).
No takes yet. Share an insight, caveat, or question.
Helin et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: